|1.||Roccatello, Dario: 4 articles (06/2013 - 12/2004)|
|2.||Witzig, Thomas E: 4 articles (03/2008 - 01/2006)|
|3.||Musto, Pellegrino: 3 articles (08/2015 - 10/2010)|
|4.||D'Auria, Fiorella: 3 articles (08/2015 - 10/2010)|
|5.||Maloney, David G: 3 articles (11/2014 - 02/2005)|
|6.||Ding, Huirong: 2 articles (12/2014 - 01/2013)|
|7.||Press, Oliver W: 2 articles (11/2014 - 04/2004)|
|8.||Smith, Justine R: 2 articles (10/2014 - 05/2014)|
|9.||Beardsley, Robert M: 2 articles (10/2014 - 05/2014)|
|10.||Butler, Nicholas J: 2 articles (10/2014 - 05/2014)|
05/01/2015 - "Two conjugates are consecutively administered: First, Fab'-CCE coats peptide CCE at CD20 antigen of lymphoma cell surface; second, CCE/CCK biorecognition between Fab'-CCE and P-(CCK)x leads to coiled-coil formation, CD20 crosslinking, membrane reorganization, and ultimately cell apoptosis. "
01/01/2007 - "This antibody against CD20 antigen, which is expressed on B cell lymphocytes and on the majority of B-cell lymphoid malignancies, has revolutionized the lymphoma therapeutic strategy. "
04/01/2005 - "The CD20 antigen has become a major therapeutic target in the management of follicular and other B cell non-Hodgkin's lymphomas. "
03/01/2002 - "CD20 antigen is expressed on nearly all human B-cells and B-lymphoma cells. "
01/01/2002 - "CD20 antigen is expressed on nearly all human B-cells and B-lymphoma cells. "
|2.||Non-Hodgkin Lymphoma (Lymphosarcoma)
12/01/2014 - "Obinutuzumab is the first fully humanized and glycoengineered monoclonal antibody (mAb) directly targeting CD20 antigen, which is expressed on B cell lymphocytes and the majority of non-Hodgkin's lymphoma (NHL). "
03/01/2011 - "CD20 antigen, which is overexpressed on cell membranes in nearly 95% of cases of B-cell Non-Hodgkin's Lymphoma, is an attractive target for the therapy of B-lymphoid malignancies. "
10/07/2006 - "The radiolabelled monoclonal antibody anti-CD20 has the property of binding to the CD20 antigen expressed on the cell surface of B-lymphocytes, thus making it a useful tool in the treatment of non-Hodgkin's lymphoma. "
06/01/2010 - "Radioimmunotherapy is approved by the Food and Drug Administration for CD20 antigen-positive follicular and transformed non-Hodgkin lymphoma. "
08/01/2003 - "Immunotherapy directed against the CD20 antigen has had a profound impact on the management of patients with B-cell non-Hodgkin's lymphoma (NHL). "
|3.||B-Cell Lymphoma (Lymphoma, B Cell)
11/01/2014 - "Thirty-nine patients with a diagnosis of B-cell lymphoma or CLL expressing the CD20 antigen, who had failed at least one prior regimen, and had evidence of persistent disease were included in this analysis; however, only 38 of them completed the treatment. "
12/01/2006 - "There has been interest in generating T cells expressing chimeric artificial receptors (CARs) targeting CD19/CD20 antigens to treat B-cell lymphomas. "
09/01/2006 - "The CD20 antigen is expressed on 95% of B-cell lymphoma cells and normal B-cells but, is not found on precursor B-cells or stem cells. "
03/01/2006 - "Both agents target the CD20 antigen on B-cell lymphoma cells. "
01/01/2006 - "Both agents target the CD20 antigen on B-cell lymphoma cells. "
08/01/2013 - "Here, we demonstrate that Salmonella tumor specificity can be significantly improved via a surface-expressed single-domain antibody directed to a tumor-associated antigen (CD20). "
01/01/2014 - "A transcriptional profiling of tumor cells incubated with SFKs inhibitors revealed strong downregulation of MS4A1 gene encoding CD20 antigen. "
03/01/2010 - "Resistance to this treatment occurs, although CD20 antigen is expressed on the tumor cells. "
01/01/2007 - "The antigen CD20 has long been thought to be a specific marker for B-cell lineage and has been used to help differentiate T-cell and B-cell neoplasms. "
01/01/2006 - "[Density expression of the CD20 antigen on population of tumor cells in patients with chronic B-lymphocyte lymphoproliferative diseases]."
|5.||Pemphigus (Pemphigus Vulgaris)
09/01/2011 - "Rituximab, a chimeric monoclonal anti-CD20 antibody, binds to the CD20 antigen on the surface of B cells and has been reported to be effective for the treatment of recalcitrant pemphigus. "
02/01/2009 - "Rituximab, a monoclonal antibody directed against the CD20 antigen of B lymphocytes, has been demonstrated to be effective in recalcitrant and life-threatening pemphigus."
01/01/2007 - "Rituximab is a chimeric monoclonal antibody binding to the CD20 antigen on B cells, which proved to be effective in recalcitrant pemphigus. "
05/01/2006 - "Rituximab is a monoclonal antibody directed against the CD20 antigen of B cells, which has been developed for the treatment of lymphomas and has been successfully used in the treatment of recalcitrant pemphigus vulgaris. "
|6.||Immunoglobulin Idiotypes (Idiotype, Immunoglobulin)
|8.||Histone Deacetylase Inhibitors
|9.||Histone Deacetylases (Histone Deacetylase)
|2.||Drug Therapy (Chemotherapy)
|3.||Homologous Transplantation (Allograft)
|4.||Transplantation (Transplant Recipients)